Studies suggest that menopausal hormone therapy (MHT) prevents type 2 diabetes (T2D). The combination of conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA) is an MHT that improves obesity and T2D in preclinical models of menopausal metabolic syndrome. The effect of CE/BZA on adiposity and glucose homeostasis in obese postmenopausal women is unknown.
Pubmed ID: 31384719 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Commercial vendor and service provider of laboratory reagents and antibodies. Supplier of scientific instrumentation, reagents and consumables, and software services.
View all literature mentionsThis unknown targets RBP4
View all literature mentionsThis unknown targets LCN2
View all literature mentionsThis unknown targets SERPINE1
View all literature mentionsThis unknown targets
View all literature mentionsThis unknown targets
View all literature mentionsThis monoclonal targets Osteocalcin
View all literature mentionsThis unknown targets C-Reactive Protein (CRP)
View all literature mentionsThis unknown targets
View all literature mentionsThis monoclonal targets FGF-21
View all literature mentionsThis monoclonal targets C-Peptide
View all literature mentionsThis unknown targets Insulin
View all literature mentions